Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 09 - 29 save search
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
Published: 2021-09-29 (Crawled : 21:00) - biospace.com/
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 0.86%
H: 2.57%
C: -2.71%
phase 3 injection infections
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
Published: 2021-09-29 (Crawled : 13:15) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.12%
H: 1.02%
C: 0.63%
respiratory vaccine phase 3 trial order
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
Published: 2021-09-29 (Crawled : 13:15) - globenewswire.com
EDIT | $5.5 -0.9% -0.91% 2.3M
|
Health Technology
|
| O: -6.58%
H: 2.45%
C: -13.27%
ongoing phase 1 positive trial phase 2 phase 3
Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021
Published: 2021-09-29 (Crawled : 13:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.33%
H: 5.54%
C: -0.81%
presentation results lenzilumab phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Published: 2021-09-29 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.7%
H: 2.16%
C: 0.9%
presentation multiple sclerosis treatment europe trials sclerosis phase 3 research trial
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
positive results vaccine phase 3 topline order
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
Published: 2021-09-29 (Crawled : 09:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 2.07%
H: 0.79%
C: -1.13%
multiple sclerosis phase 1 sclerosis iot phase 2 phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.